Innovative Therapies for Schizophrenia, Atopic Dermatitis, Hepatitis B, and SLE Highlighted at CIIE
Key Insights
Johnson & Johnson launched INVEGA HAFYERA in China, a twice-yearly injection for schizophrenia (search) treatment, marking its debut after being introduced at CIIE 2022.
Pfizer showcased Cibinqo and Staquis as innovative therapies for atopic dermatitis (search) (AD), addressing a common immuno-inflammatory disease affecting millions in China.
GSK's Bepirovirsen, a potential 'functional cure' for chronic hepatitis B (search), is undergoing Phase III clinical studies and has received breakthrough therapy designation in China.
The 7th China International Import Expo (CIIE) in Shanghai featured the unveiling of several advanced medical technologies and solutions by multinational pharmaceutical companies. These innovations aim to address significant healthcare challenges in China, ranging from psychiatric disorders to immunological and infectious diseases.
Johnson & Johnson Launches Long-Acting Schizophrenia Treatment
Johnson & Johnson announced the China market launch of INVEGA HAFYERA, a long-acting injectable medication for the treatment of schizophrenia (search) in adults. This therapy, administered only twice a year, represents a significant advancement in patient convenience and adherence. Edward Zhou, president of Johnson & Johnson MedTech China, emphasized the company's commitment to introducing advanced medical technologies to the Chinese market and promoting local innovations globally.
Pfizer Showcases Innovative Dermatology Solutions for Atopic Dermatitis
Pfizer's inflammation and immunology business unit highlighted its breakthrough dermatology solutions, including Cibinqo and Staquis, for the treatment of atopic dermatitis (search) (AD). AD, characterized by chronic itching and skin lesions, affects millions in China. These therapies offer comprehensive treatment options for patients with mild, moderate, and severe forms of the disease.
GSK's Bepirovirsen Advances Towards Functional Cure for Hepatitis B
GSK announced that its innovative drug Bepirovirsen is currently in Phase III clinical studies and has been granted breakthrough therapy designation by China's Center for Drug Evaluation. Bepirovirsen is being developed as a potential "functional cure" for chronic hepatitis B (search). Studies have demonstrated its potential in addressing the ongoing challenges of hepatitis B prevention and control in China, where a large population base continues to be affected.
GSK Presents SLE Therapy and Launches Patient Support Program
Showcasing its innovative therapy for systemic lupus erythematosus (search) (SLE (search)), an autoimmune disease, GSK also announced the launch of a public welfare project at the CIIE. This project aims to support SLE patients and various stakeholders, with the goal of improving diagnosis and treatment levels and enhancing the living environment for patients affected by this condition.